News
IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis
UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including
